#Ireland #Galway #Neurent Medical #NEUROMARK #Claret Capital

Neurent Medical Secures €25 Million Growth Debt Facility

Neurent Medical, a leading innovator in the treatment of chronic rhinitis, has successfully secured a growth debt facility totaling €25 million from Claret Capital Partners. This funding will significantly bolster the company's expansion efforts, particularly in the sales and marketing domains essential for the NEUROMARK® system, their revolutionary minimally invasive treatment for chronic rhinitis.

The announcement made on September 9, 2026, highlights Neurent Medical's commitment to enhancing patient care through innovative solutions. This financing arrives shortly after the company completed a robust €62.5 million in Series C financing earlier this year, reinforcing its strong market position in treating chronic sinonasal diseases. These funding efforts are indicative of Neurent's dedication to transforming the industry landscape and improving patient access to cutting-edge treatment options.

CEO Brian Shields expressed his enthusiasm regarding the recent funding. He stated, "This financing marks another significant milestone for Neurent Medical as we scale our commercial operations to reach more patients with NEUROMARK. We value our partnership with Claret Capital Partners, whose unwavering support demonstrates their confidence in our technology and clinical evidence. The facility provides us with considerable financial flexibility, enabling us to execute our growth strategy without diluting our shareholders' interests."

Claret Capital Partners, Europe's premier independent growth debt fund manager, has shown a longstanding commitment to supporting innovative companies. Daniel Mallon, a Principal at Claret Capital, commented on Neurent's impressive progress in establishing NEUROMARK as a leading solution for chronic rhinitis. He expressed satisfaction in supporting Neurent's continuous expansion, which aims to enhance outcomes for millions struggling with this condition.

The NEUROMARK® system employs proprietary impedance-controlled radiofrequency technology, designed to precisely target hyperactive posterior nasal nerves. This approach offers durable relief to patients suffering from the debilitating symptoms of chronic rhinitis, contributing to a better quality of life. By focusing on minimally invasive treatment options, Neurent Medical not only bridges the gap between patient needs and available treatment options but also positions itself as a leader in the healthcare industry.

Headquartered in Galway, Ireland, with operational facilities in Braintree, Massachusetts, Neurent Medical is at the forefront of health innovation. The recent financing will allow the company to bolster its operations and continue its mission of transforming chronic rhinitis treatment.

In conclusion, as Neurent Medical moves forward with its plans to expand, the support from Claret Capital will facilitate critical growth initiatives that may alter the treatment trajectory for chronic rhinitis sufferers. Investors, healthcare professionals, and patients alike will be keenly observing how these developments unfold, enhancing clinical care and access to effective solutions in the field of chronic respiratory conditions. With such strategic financial backing, Neurent Medical is poised not only to enhance its offerings but to become a pivotal player in medical technology dedicated to long-term patient relief.